The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
Open accessAbstract
The Polycomb Group Protein EZH2 is a transcriptional repressor involved in controlling cellular memory and has been linked to aggressive prostate cancer. Here we investigate the functional role of EZH2 in cancer cell invasion and breast cancer progression. EZH2 transcript and protein were consistently elevated in invasive breast carcinoma compared with normal breast epithelia. Tissue microarray analysis, which included 917 samples from 280 patients, demonstrated that EZH2 protein levels were strongly associated with breast cancer aggressiveness. Overexpression of EZH2 in immortalized human mammary epithelial cell lines promotes anchorage-independent growth and cell invasion. EZH2-mediated cell invasion required an intact SET domain and histone deacetylase activity. This study provides compelling evidence for a functional link between dysregulated cellular memory, transcriptional repression, and neoplastic transformation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The increased response rates in EZH2-mutant tumours mirrors preclinical studies and highlights the importance of understanding the mechanisms underlying EZH2 dependence”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [167]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Ki67 expression in breast cancer
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Self-citationHaagenson, C. (1971) · Cited by 1,773
Research works printed but not linked: 7
- Ellis M. Hayes D. & Lippman M. (2000) in Diseases of the Breast eds. Harris J. Lippman M. E. & Morrow M. (Lippincott–Raven Philadelpha) pp. 749–798.
- Clark G. M. (1996) in Diseases of the Breast eds. Harris. J. L. M.. Morrow M. & Hellman S. (Lippincott–Raven Philadephia) pp. 461–485.
- Tie, F., Furuyama, T., Prasad-Sinha, J., Jane, E. & Harte, P. J. (2001) Development (Cambridge, U.K.) 128, 275–286.
- Livant, D. L., Linn, S., Markwart, S. & Shuster, J. (1995) Cancer Res. 55, 5085–5093.7585556
- Rhodes, D. R., Barrette, T. R., Rubin, M. A., Ghosh, D. & Chinnaiyan, A. M. (2002) Cancer Res. 62, 4427–4433.12154050
- Gruvberger, S., Ringner, M., Chen, Y., Panavally, S., Saal, L. H., Borg, A., Ferno, M., Peterson, C. & Meltzer, P. S. (2001) Cancer Res. 61, 5979–5984.11507038
- Livant, D. L., Brabec, R. K., Pienta, K. J., Allen, D. L., Kurachi, K., Markwart, S. & Upadhyaya, A. (2000) Cancer Res. 60, 309–320.10667582
Cited by
Sorted by citations
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis
Gupta, R. A., Shah, N., Wang, K., Kim, J., Horlings, H. M., Wong, D. J., Tsai, M.-C., Hung, T., Argani, P., Rinn, J. L., et al. (2010) · Nature · doi:10.1038/nature08975 · Cited by 5,205
Ginestier, C., Hur, M. H., Charafe‐Jauffret, E., Monville, F., Dutcher, J. A., Brown, M., Jacquemier, J. D., Viens, P., Kleer, C. G., Liu, S., et al. (2007) · Cell stem cell · doi:10.1016/j.stem.2007.08.014 · Cited by 4,093
Self-citationThe Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347
Metastasis: from dissemination to organ-specific colonization
Nguyen, D. X., Bos, P. D., & Massagué, J. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2622 · Cited by 2,716
Histone methylation: a dynamic mark in health, disease and inheritance
Greer, E. L., & Shi, Y. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3173 · Cited by 2,241
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
Sreekumar, A., Poisson, L., Rajendiran, T. M., Khan, A. P., Cao, Q., Yu, J., Laxman, B., Mehra, R., Lonigro, R. J., Li, Y., et al. (2009) · Nature · doi:10.1038/nature07762 · Cited by 2,269
Self-citationEZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786
Morin, R. D., Johnson, N. A., Severson, T., Mungall, A. J. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F. C., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,719
Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?
Baylin, S. B., & Ohm, J. E. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1799 · Cited by 1,657
Kim, K. H., & Roberts, C. W. M. (2016) · Nature Medicine · doi:10.1038/nm.4036 · Cited by 1,471
Polycomb silencers control cell fate, development and cancer
Sparmann, A., & van Lohuizen, M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1991 · Cited by 1,339
Writing, erasing and reading histone lysine methylations
Hyun, K., Jeon, J., Park, K., & Kim, J. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.11 · Cited by 1,250
The epigenetics of epithelial-mesenchymal plasticity in cancer
Tam, W. L., & Weinberg, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3336 · Cited by 1,208
Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancers
Chi, P., Allis, C. D., & Wang, G. G. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2876 · Cited by 1,131
Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer
Varambally, S., Cao, Q., Mani, R. S., Shankar, S., Wang, X., Ateeq, B., Laxman, B., Cao, X., Jing, X., Ramnarayanan, K., et al. (2008) · Science · doi:10.1126/science.1165395 · Cited by 1,064
Self-citationPrensner, J. R., Iyer, M. K., Balbin, O. A., Dhanasekaran, S. M., Cao, Q., Brenner, J. C., Laxman, B., Asangani, I. A., Grasso, C. S., Kominsky, H. D., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1914 · Cited by 1,037
Self-citationRhodes, D. R., Yu, J., Sundaram, S. K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T. R., Pandey, A., & Chinnaiyan, A. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401994101 · Cited by 1,018
Self-citationEZH2: a novel target for cancer treatment
Duan, R., Du, W., & Guo, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00937-8 · Cited by 980
Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity
Pasini, D., Bracken, A. P., Jensen, M. R., Denchi, E. L., & Helin, K. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600402 · Cited by 963
The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3
Cao, R., & Zhang, Y. (2004) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.02.001 · Cited by 944
Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., Karuturi, R. K. M., Tan, P. B. O., Liu, E. T., & Yu, Q. (2007) · Genes & Development · doi:10.1101/gad.1524107 · Cited by 895
Triple-negative breast cancer in African-American women: disparities versus biology
Dietze, E. C., Sistrunk, C., Miranda‐Carboni, G. A., O'Regan, R. M., & Seewaldt, V. L. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3896 · Cited by 912
Chaffer, C. L., Marjanovic, N. D., Lee, T., Bell, G. W., Kleer, C. G., Reinhardt, F., D’Alessio, A. C., Young, R. A., & Weinberg, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.06.005 · Cited by 903
Self-citationRoles of the EZH2 histone methyltransferase in cancer epigenetics
Simon, J. A., & Lange, C. A. (2008) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2008.07.010 · Cited by 880
Bachmann, I. M., HALVORSEN, O. J., Collett, K., Stefansson, I. M., Straume, O., Haukaas, S. A., Salvesen, H. B., Otte, A. P., & Akslen, L. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5180 · Cited by 860
Self-citationNovel mutations target distinct subgroups of medulloblastoma
Robinson, G. W., Parker, M. D., Kranenburg, T. A., Lu, C., Chen, X. '., Ding, L., Phoenix, T. N., Hedlund, E., Wei, L., Zhu, X., et al. (2012) · Nature · doi:10.1038/nature11213 · Cited by 853
hDOT1L Links Histone Methylation to Leukemogenesis
Okada, Y., Feng, Q. F., Lin, Y.-H., Jiang, Q., Li, Y., Coffield, V. M., Su, L., Xu, G., & Zhang, Y. (2005) · Cell · doi:10.1016/j.cell.2005.02.020 · Cited by 835
Kim, E. H., Kim, M., Woo, D., Shin, Y., Shin, J., Chang, N., Oh, Y. T., Kim, H., Rheey, J., Nakano, I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.008 · Cited by 846
Cao, R., & Zhang, Y. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.06.020 · Cited by 856
Genetic determinants of cancer metastasis
Nguyen, D. X., & Massagué, J. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2101 · Cited by 814
Varambally, S., Yu, J., Laxman, B., Rhodes, D. R., Mehra, R., Tomlins, S. A., Shah, R. B., Chandran, U. R., Monzon, F. A., Becich, M. J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.001 · Cited by 805
Self-citationThe SET-domain protein superfamily: protein lysine methyltransferases.
Dillon, S. C., Zhang, X. Y., Trievel, R. C., & Cheng, X. (2005) · Genome biology · doi:10.1186/gb-2005-6-8-227 · Cited by 840
A histone H3 lysine 27 demethylase regulates animal posterior development
Lan, F., Bayliss, P. E., Rinn, J. L., Whetstine, J. R., Wang, J. K., Chen, S., Iwase, S., Alpatov, R., Issaeva, I., Canaani, E., et al. (2007) · Nature · doi:10.1038/nature06192 · Cited by 808
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1084 · Cited by 776
The key to development: interpreting the histone code?
Margueron, R., Trojer, P., & Reinberg, D. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2005.01.005 · Cited by 770
Valk-Lingbeek, M. E., Bruggeman, S. W. M., & van Lohuizen, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.005 · Cited by 743
Sneeringer, C. J., Scott, M. P., Kuntz, K. W., Knutson, S. K., Pollock, R. M., Richon, V. M., & Copeland, R. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012525107 · Cited by 719
Polycomb Group Proteins: Multi-Faceted Regulators of Somatic Stem Cells and Cancer
Sauvageau, M., & Sauvageau, G. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.002 · Cited by 586
Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic Transformation
Wilson, B. G., Wang, X., Shen, X., McKenna, E. S., Lemieux, M. E., Cho, Y., Koellhoffer, E. C., Pomeroy, S. L., Orkin, S. H., & Roberts, C. W. M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.09.006 · Cited by 671
Kondo, Y., Shen, L., Cheng, A. S. L., Ahmed, S., Boumber, Y., Charo, C., Yamochi, T., Urano, T., Furukawa, K., Kwabi‐Addo, B., et al. (2008) · Nature Genetics · doi:10.1038/ng.159 · Cited by 632
Yap, D., Chu, J., Berg, T., Schapira, M., Cheng, S., Moradian, A., Morin, R. D., Mungall, A. J. J., Meissner, B., Boyle, M., et al. (2010) · Blood · doi:10.1182/blood-2010-11-321208 · Cited by 633
P53 expression in breast cancer
Cattoretti, G., Rilke, F. O., Andreola, S. A., D'Amato, L., & Delia, D. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910410204 · Cited by 597
G, C., Padova, M. D., GE, L., Lyons, G. E., & Sartorelli, V. (2004) · Genes & Development · doi:10.1101/gad.1241904 · Cited by 611
Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host
Timp, W., & Feinberg, A. P. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3486 · Cited by 611
Hon, G. C., Hawkins, R. D., Caballero, O. L., Lo, C., Lister, R., Pelizzola, M., Valsesia, A., Ye, Z., Kuan, S., Edsall, L. E., et al. (2012) · Genome Research · doi:10.1101/gr.125872.111 · Cited by 583
Repression of E-cadherin by the polycomb group protein EZH2 in cancer
Cao, Q., Yu, J., Dhanasekaran, S. M., Kim, J. H., Mani, R. S., Tomlins, S. A., Mehra, R., Laxman, B., Cao, X., Yu, J., et al. (2008) · Oncogene · doi:10.1038/onc.2008.333 · Cited by 592
Self-citationPolycomb group proteins: navigators of lineage pathways led astray in cancer
Bracken, A. P., & Helin, K. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2736 · Cited by 523
Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3
Cha, T., Zhou, B. P., Xia, W., Wu, Y., Yang, C., Chen, C., Ping, B., Otte, A. P., & Hung, M. (2005) · Science · doi:10.1126/science.1118947 · Cited by 563
Self-citationThe roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549
Chase, A., & Cross, N. C. P. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2156 · Cited by 563
Miao, Z., Luker, K. E., Summers, B. C., Berahovich, R., Bhojani, M. S., Rehemtulla, A., Kleer, C. G., Essner, J. J., Nasevicius, A., Luker, G. D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610444104 · Cited by 528
Self-citationBreast cancer diagnosis: Imaging techniques and biochemical markers
Jafari, S. H., Saadatpour, Z., Salmaninejad, A., Momeni, F., Mokhtari, M., Nahand, J. S., Rahmati, M., Mirzaei, H., & Kianmehr, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26379 · Cited by 410
Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27Preprint
Kirmizis, A., Bartley, S. M., Kuzmichev, A., Margueron, R., Reinberg, D., Green, R., & Farnham, P. (2004) · Genes & Development · doi:10.1101/gad.1200204 · Cited by 503
Lund, A. H., & van Lohuizen, M. (2004) · Genes & Development · doi:10.1101/gad.1232504 · Cited by 489
Tiwari, N., Tiwari, V. K., Waldmeier, L., Balwierz, P. J., Arnold, P., Pachkov, M. V., Meyer‐Schaller, N., Schübeler, D., van Nimwegen, E., & Christofori, G. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.020 · Cited by 494
Protein methyltransferases as a target class for drug discovery
Copeland, R. A., Solomon, M. E., & Richon, V. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2974 · Cited by 480
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma
Palanisamy, N., Ateeq, B., Sundaram, S. K., Pflueger, D., Ramnarayanan, K., Shankar, S., Han, B., Cao, Q., Cao, X., Suleman, K., et al. (2010) · Nature Medicine · doi:10.1038/nm.2166 · Cited by 460
Self-citationPlass, C., Pfister, S. M., Lindroth, A. M., Bogatyrova, O., Claus, R., & Lichter, P. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3554 · Cited by 458
Geiger, T. R., & Peeper, D. S. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.07.006 · Cited by 472
Chromatin proteins and modifications as drug targets
Helin, K., & Dhanak, D. (2013) · Nature · doi:10.1038/nature12751 · Cited by 448
The Human Tumor Antigen PRAME Is a Dominant Repressor of Retinoic Acid Receptor Signaling
Epping, M. T., Wang, L., Edel, M. J., Carlée, L., Hernandez, M., & Bernards, R. (2005) · Cell · doi:10.1016/j.cell.2005.07.003 · Cited by 432
Maintaining cell identity: PRC2-mediated regulation of transcription and cancer
Comet, I. V., Riising, E. M., Leblanc, B., & Helin, K. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.83 · Cited by 441
Epigenetics in cancer stem cells
Toh, T. B., Lim, J. J., & Chow, E. K. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0596-9 · Cited by 439
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
Mohammad, H. P., Barbash, O., & Creasy, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0376-8 · Cited by 427
Taby, R. F., & Issa, J. J. (2010) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20085 · Cited by 429
Chromatin remodeling and cancer, part I: covalent histone modifications
Wang, G. G., Allis, C. D., & Chi, P. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.07.003 · Cited by 423
The cancer epigenome—components and functional correlatesPreprint
Ting, A. H., McGarvey, K. M., & Baylin, S. B. (2006) · Genes & Development · doi:10.1101/gad.1464906 · Cited by 419
Chang, C. J., Yang, J.-Y., Xia, W., Chen, C.-T., Xie, X., Chao, C.-H., Woodward, W. A., Hsu, J.-M., Hortobágyi, G. N., & Hung, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.035 · Cited by 423
Kuzmichev, A., Margueron, R., Vaquero, A., Preissner, T. S., Scher, M. B., Kirmizis, A., Ouyang, X., Brockdorff, N., Abate-Shen, C. T., Farnham, P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409875102 · Cited by 418
Comprehensive review on current developments of quinoline-based anticancer agents
Jain, S., Chandra, V., Jain, P. K., Pathak, K., Pathak, D., & Vaidya, A. (2016) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2016.10.009 · Cited by 406
Regulation of Tumor Angiogenesis by EZH2
Lu, C., Han, H. D., Mangala, L. S., Ali‐Fehmi, R., Newton, C. S., Ozbun, L. L., Armaiz-Peña, G. N., Hu, W., Stone, R. L., Munkarah, A. R., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.016 · Cited by 411
Pasini, D., Malatesta, M., Jung, H. R., Walfridsson, J., Willer, A., Olsson, L., Skotte, J., Wutz, A., Porse, B. T., Jensen, O. N., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq244 · Cited by 413
Context-Specific Regulation of NF-κB Target Gene Expression by EZH2 in Breast Cancers
Lee, S. T., Li, Z., Wu, Z., Aau, M., Guan, P., Karuturi, R. K. M., Liou, Y. C., & Yu, Q. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.011 · Cited by 412
Song, L.-B., Li, J., Liao, W., Feng, Y., Yu, C.-P., Hu, L.-J., Kong, Q., Xu, L.-H., Zhang, X., Liu, W.-L., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39374 · Cited by 402
Chinnaiyan, P., Huang, S., Vallabhaneni, G. D., Armstrong, E. A., Varambally, S., Tomlins, S. A., Chinnaiyan, A. M., & Harari, P. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3547 · Cited by 388
Self-citationLü, J., He, M., Wang, L., Chen, Y., Liu, X., Dong, Q., Chen, Y., Peng, Y., Yao, K., Kung, H., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1850 · Cited by 383
Friedman, J. M., Liang, G., Liu, C.-C., Wolff, E. M., Tsai, Y., Ye, W., Zhou, X. J., & Jones, P. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3114 · Cited by 391
Wei, Y., Chen, Y.-H., Li, L., Lang, J., Yeh, S., Shi, B., Yang, C., Yang, J.-Y., Lin, C.-Y., Lai, C., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2139 · Cited by 388
The polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion
Kamminga, L. M., Bystrykh, L. V., de Boer, A., Houwer, S., Douma, J., Weersing, E., Dontje, B., & de Haan, G. (2006) · Blood · doi:10.1182/blood-2005-09-3585 · Cited by 376
Verma, S. K., Tian, X., LaFrance, L. V., Duquenne, C., Suarez, D., Newlander, K. A., Romeril, S. P., Burgess, J. L., Grant, S. W., Brackley, J. A., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3003346 · Cited by 390
Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer
Brooks, M., Burness, M. L., & Wicha, M. S. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.08.014 · Cited by 383
Polycomb Group Protein Ezh2 Controls Actin Polymerization and Cell Signaling
Su, I.-H., Dobenecker, M.-W., Dickinson, E., Oser, M., Basavaraj, A., Marqueron, R., Viale, A., Reinberg, D., Wülfing, C., & Tarakhovsky, A. (2005) · Cell · doi:10.1016/j.cell.2005.02.029 · Cited by 365
Fiskus, W. C., Wang, Y., Sreekumar, A., Buckley, K. M., Shi, H., Jillella, A., Üstün, C., Rao, R., Fernandez, P., Chen, J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-213496 · Cited by 372
Chromatin repressive complexes in stem cells, development, and cancer
Laugesen, A., & Helin, K. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.05.006 · Cited by 352
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo
Takeshita, F., Minakuchi, Y., Nagahara, S., Honma, K., Sasaki, H., Hirai, K., Teratani, T., Namatame, N., Yamamoto, Y., Hanai, K., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501753102 · Cited by 353
A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome
Yu, J., Yu, J., Rhodes, D. R., Tomlins, S. A., Cao, X., Chen, G., Mehra, R., Wang, X., Ghosh, D., Shah, R. B., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2498 · Cited by 349
Self-citationShi, B., Liang, J., Yang, X., Wang, Y., Zhao, Y., Wu, H., Sun, L., Zhang, Y., Chen, Y., Li, R., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00162-07 · Cited by 355
Onco-Multi-OMICS Approach: A New Frontier in Cancer Research
Chakraborty, S., Hosen, M. I., Ahmed, M., & Shekhar, H. U. (2018) · BioMed Research International · doi:10.1155/2018/9836256 · Cited by 347
Targeted disruption of the EZH2–EED complex inhibits EZH2-dependent cancer
Kim, W., Bird, G. H., Neff, T., Guo, G., Kerenyi, M. A., Walensky, L. D., & Orkin, S. H. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1331 · Cited by 351
Doherty, L. F., Bromer, J. G., Zhou, Y., Aldad, T. S., & Taylor, H. S. (2010) · Hormones and Cancer · doi:10.1007/s12672-010-0015-9 · Cited by 353
Histone lysine methylation and demethylation pathways in cancer
Varier, R. A., & Timmers, H. T. M. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.10.002 · Cited by 351
Li, Z., Hou, P., Fan, D., Dong, M., Ma, M., Li, H., Yao, R., Li, Y., Wang, G., Geng, P., et al. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.95 · Cited by 338
Nimer, S. D. (2008) · Blood · doi:10.1182/blood-2007-08-078139 · Cited by 339
Chromatin modifier enzymes, the histone code and cancer
Santos-Rosa, H., & Caldas, C. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.010 · Cited by 356
HIV-1 transcription and latency: an update
Lint, C. M. V., Bouchat, S., & Marcello, A. (2013) · Retrovirology · doi:10.1186/1742-4690-10-67 · Cited by 352
The Dual Role of Sirtuins in Cancer
Bosch‐Presegué, L., & Vaquero, A. (2011) · Genes & Cancer · doi:10.1177/1947601911417862 · Cited by 337
Song, L.-B., Zeng, M., Liao, W., Zhang, L., Mo, H., Liu, W.-L., Shao, J., Wu, Q., Li, M.-Z., Xia, Y.-F., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0094 · Cited by 331
Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Aarts, M., Sharpe, R., García-Murillas, I., Gevensleben, H., Hurd, M. S., Shumway, S. D., Toniatti, C., Ashworth, A., & Turner, N. C. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0320 · Cited by 327
Identification of GATA3 as a Breast Cancer Prognostic Marker by Global Gene Expression Meta-analysis
Mehra, R., Varambally, S., Ding, L., Shen, R., Sabel, M. S., Ghosh, D., Chinnaiyan, A. M., & Kleer, C. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2495 · Cited by 328
Self-citation
Metadata
- Authors
- Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., Sabel, M. S., Livant, D., Weiss, S. J., Rubin, M. A., & Chinnaiyan, A. M.
- Affiliations
- Brigham and Women's Hospital (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2003-09-19
- Volume
- 100
- Issue
- 20
- Pages
- 11606-11611
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC208805
- OpenAlex
- W2100365251
- Cited by
- 1,649
- References
- 38
- Citations by year
- 2026: 21 · 2025: 43 · 2024: 53 · 2023: 72 · 2022: 55 · 2021: 67 · 2020: 94 · 2019: 69 · 2018: 83 · 2017: 91 · 2016: 109 · 2015: 109 · 2014: 116 · 2013: 114 · 2012: 108
- FWCI
- 12.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UvA-DARE (University of Amsterdam) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Cancer Institute (P50-CA-69568, R01CA097063, R01 CA97063, P50CA069568)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- EZH2, Polycomb group proteins, breast cancer aggressiveness, breast cancer progression, cell invasion, anchorage-independent growth, oncogenic transformation, mammary epithelial cells, SET domain, histone deacetylase activity, transcriptional repression, cellular memory, prognostic factors
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, Breast, Breast Neoplasms, Cell Transformation, Neoplastic, DNA-Binding Proteins, Epithelial Cells, Female, Humans, Immunohistochemistry, Proteins, RNA, Messenger, Transcription Factors, Polymerase Chain Reaction, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
